TrivarX Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	1.1yrs
Board average tenure	2.7yrs

Recent management updates

Recent updates

CEO

TrivarX has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kai Sun	Chief Operating Officer	less than a year	no data	no data
Josh Purdy	Public Relations Director	no data	no data	no data
Archie Defillo	Chief Medical Officer	no data	no data	no data
Massimiliano Grassi	Head of Artificial Intelligence	4.3yrs	no data	no data
Stephen Buckley	Company Secretary	1.1yrs	no data	no data

1.1yrs

Average Tenure

Experienced Management: TRI's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Christopher Ntoumenopoulos	Non-Executive Director	1.3yrs	AU$22.89k	1.26% A$ 127.9k
Peter Carlisle	Chairman of Growth & Advocacy Advisory Board	6.9yrs	AU$48.02k	no data
Patrick Kennedy	Member of Growth & Advocacy Advisory Board	4.8yrs	no data	no data
Michael Phelps	Member of Growth & Advocacy Advisory Board	4.8yrs	no data	no data
David Trimboli	Independent Non-Executive Chairman	1.8yrs	AU$61.79k	no data
Elizabeth Lombardo	Member of Growth & Advocacy Advisory Board	2.7yrs	no data	no data
Thomas Young	Non-Executive Director	1.1yrs	AU$138.26k	no data

2.7yrs

Average Tenure

Experienced Board: TRI's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.

TrivarX Management

Management criteria checks 0/4

Key information

Recent management updates

Medibio Limited, Annual General Meeting, Nov 29, 2023

Medibio Limited, Annual General Meeting, Oct 06, 2023

Medibio Limited Appoints Christopher Ntoumenopoulos as Director

Less than half of directors are independent

Medibio Limited Announces Resignation of Stephen Mitchley as a Director

Medibio Limited Appoints David Trimboli as the Company's New Non-Executive Chair

Recent updates

TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Medibio Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022)

Medibio Limited, Annual General Meeting, Oct 06, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released

Medibio Limited Appoints Christopher Ntoumenopoulos as Director

Less than half of directors are independent

Medibio Limited Announces Resignation of Stephen Mitchley as a Director

Medibio Limited Appoints David Trimboli as the Company's New Non-Executive Chair

Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021)

Medibio Limited, Annual General Meeting, Nov 11, 2022

Medibio Limited Appoints Thomas R. Young as CEO

Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021)

Medibio Appoints David Trimboli to Its Board of Directors as Non-Executive Director

Medibio Limited Announces Sleep Analysis Depressive Burden Study Clinical Trial Commencement

Medibio Limited Announces Resignation of Claude Solitario as Managing Director

Medibio Limited Announces Executive Changes

Medibio Limited Announces That A DSM-V1 Diagnosis Will Be Included as Primary Comparator for the Purposes of Assessing the Efficacy of Its Depression Algorithms, MEB-001

Less than half of directors are independent

Medibio Limited Appoints Matt Mesnik as Non-Executive Director

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Medibio Limited Appoints Stephen Mitchley as Non-Executive Director

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.004 loss in FY 2020)

Medibio Limited to Resubmit FDA 510(K) Application for its Sleep Staging Software, MEBbsleep

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.003 loss in 1H 2020)

Medibio Limited, Annual General Meeting, Mar 24, 2021

Medibio Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Medibio Limited Receives CE Mark Approval for Its Sleep Staging Software, MEBsleep

Medibio Limited Commences the Initial Phase of Testing of its Consumer Mental Health App

Medibio Limited Announces US FDA Advises Further Data Needed for Mebsleep Approval

Medibio Limited Signs Global Master License & Services Agreement with Compass Group Plc

Medibio Limited Signs Clinical Trial Agreement with MedBridge Healthcare

Medibio Limited Submits Request for FDA Breakthrough Device Designation

Full year earnings released - AU$0.0044 loss per share

Full year earnings released - AU$0.0044 loss per share

Medibio Limited has completed a Follow-on Equity Offering in the amount of AUD 1.517195 million.

CEO

Leadership Team

Average Tenure

Board Members

Average Tenure